# GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

> **NCT03320642** · PHASE1 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 84 (actual)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **DRUG:** Itacitinib
- **DRUG:** Calcineurin inhibitor

## Key facts

- **NCT ID:** NCT03320642
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-27
- **Primary completion:** 2021-02-25
- **Final completion:** 2022-02-17
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Study terminated by sponsor
- **Last updated:** 2025-10-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03320642

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03320642, "GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03320642. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*